Last 11 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — | — | 27.15 | 55.56 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.15 | 0.00 | 0.00 | 2.44 | 1.13 | — | — | 0.00 | 1.32 | 1.30 | 1.34 | — |
| — | — | — | +239098.0% | -14.3% | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.7% | -16.2% | -10.7% | -9.0% | -40.9% | — | — | -10.5% | -9.3% | -11.9% | -17.0% | — |
| — | — | — | +13.8% | -337.7% | — | — | — | — | — | — | — | |
| ROA | -41.7% | -14.2% | -9.7% | -8.3% | -14.1% | -18.9% | -12.8% | -10.2% | -9.1% | -11.6% | -16.4% | -12.5% |
| — | +24.7% | +24.1% | +18.3% | -55.3% | -63.3% | +22.1% | +18.7% | — | — | — | — | |
| ROIC | -96.3% | -15.2% | -19.1% | -80.4% | — | — | — | -8.8% | -8.0% | -9.9% | -12.9% | — |
| — | — | — | -810.7% | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 12.14 | 4.69 | 6.16 | 12.14 | 13.33 | 5.22 | 5.87 | 10.40 | 16.12 | 26.23 | 90.42 | — |
| — | -10.1% | +4.9% | +16.8% | -17.3% | -80.1% | -93.5% | — | — | — | — | — | |
| Quick Ratio | 12.14 | 4.69 | 6.16 | 12.14 | 13.33 | 5.22 | 5.87 | 10.40 | 16.12 | 26.23 | 90.42 | — |
| — | -10.1% | +4.9% | +16.8% | -17.3% | -80.1% | -93.5% | — | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 11 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BBOT stock.
BridgeBio Oncology Therapeutics Inc.'s current P/E is -0.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BridgeBio Oncology Therapeutics Inc.'s business trajectory between earnings reports.